Background
Methods
Patients
Number of patients (%) | |
---|---|
Gender
| |
Female | 31 (26.3%) |
Male | 87 (73.8%) |
Histological type
| |
Clear cell RCC | 99 (83.9%) |
Papillary RCC | 9 (7.63%) |
Chromophobe RCC | 5 (4.24%) |
Other* | 5 (4.24%) |
Histological grade (Fuhrman)
| |
I | 6 (5.08%) |
II | 46 (38.98%) |
III | 48 (40.68%) |
IV | 18 (15.25%) |
Stage
| |
I | 28 (23.73%) |
II | 15 (12.71%) |
III | 24 (20.34%) |
IV | 39 (33.05%) |
Not available | 12 (10.17%) |
Lymph node metastasis
| |
No | 73 (61.8%) |
Yes | 20 (17%) |
Not available | 25 (21.2%) |
Total number of metastases
| |
Absence | 30 (25.42%) |
1 | 25 (21.19% |
2 | 24 (20.34%) |
3 | 11 (9.32%) |
4 | 4 (3.39%) |
Not available | 24 (20.24%) |
Disease progression
| |
Absence | 19 (16.10%) |
Presence | 42 (35.60%) |
Not available | 57 (48.30%) |
Follow-up
| |
Alive/censored | 43 (45.74%) Follow-up: 49 months (6-108.8 months) |
Dead of disease | 51 (54.26%) Follow-up: 30.37 months (1.77-117.43 months) |
Median (range)
| |
Age
| 61 (30-80) |
Immunohistochemical staining
Protein | No of cases | Clone | Company | Catalog no. | Raised in | Positive controls | Antigen retrieval method | Dilution and incubation time for immunohistochemistry |
---|---|---|---|---|---|---|---|---|
IL-8 | 118 | Polyclonal | Invitrogen Corporation, Camarillo, CA | AHC 0881 | Rabbit | Normal tonsillar tissue | pH 6 (low) | 1:50, 18 h 4°C |
IL-6 | 118 | Polyclonal | Santa Cruz Biotechnology, Santa Cruz, CA | SC 1265 | Goat | Normal tonsillar tissue | pH 6 (low) | 1:50, 18 h 4°C |
SOCS-3 | 118 | Polyclonal | Santa Cruz Biotechnology, Santa Cruz, CA | SC 9023 | Rabbit | Cholangiocarcinoma | pH 6 (low) | 1:100, 18 h 4°C |
CXCR2 | 118 | Monoclonal | R&D Systems, Abingdon, England | MAB 331 | Mouse | Normal tonsillar tissue | pH 9 (high) | 1:100, 18 h 4°C |
VEGF | 117 | Monoclonal | Pharmingen BD Company, San Diego, CA | clone G153-694 | Mouse | Glioblastoma | pH 6 (low) | 1:40, 18 h 4°C |
p-STAT3 [specific at site Tyr 705] | 117 | Monoclonal | Cell Signaling Technology Inc., Boston, MA, USA | D3A7 XP | Rabbit | Human breast cancer | pH 6 (low) | 1:100, 18 h 4°C |
CD31 | 111 | Monoclonal | DAKO | clone JC70A | Mouse | Kaposi sarcoma | pH 9 (high) | 1:20, 18 h 4°C |
P53 | 30 | Monoclonal | DAKO | IR616 | Mouse | Serous ovarian carcinoma | pH 6(low) | Pre-diluted, 1 h 37°C |
HIF-1a | 30 | Monoclonal | Neomarkers Inc. Fremont CA, USA | MS 1164P | Mouse | Glioblastoma | pH 6(low) | Pre-diluted, 1 h 37°C |
p65/RelA | 30 | Polyclonal | Zymed laboratories Inc., California, USA | 18-7308 | Rabbit | breast carcinoma | pH 6(low) | 1:300, overnight 37°C |
Western immunoblotting analysis
Statistical analysis
Results
Western blot analysis
Immunohistochemical assessment of IL-6, IL-8 and CXCR2 expression in RCC and correlation with clinicopathological parameters
IL-6 | IL-8 | CXCR2 | SOCS-3 | p-STAT-3 | VEGF | |
---|---|---|---|---|---|---|
IL-8
| NS* | |||||
CXCR2
| R = 0.2393, p = 0.0091*** | R = 0.2989, p = 0.0010 | NS | |||
SOCS-3
| NS | NS | NS | NS | ||
p-STAT3
| NS | NS | NS | NS | NS | |
VEGF
| R = 0.2623, p = 0.0054 | R = 0.1217, p = 0.0730 | R = 0.3549, p = 0.0001 | R = 0.2540, p = 0.0071** | NS | NS |
IL-6 H-score | IL-8 H-score | CXCR2 H-score | SOCS-3 H-score | p-STAT-3 H-score | VEGF H-score | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Median (range) | p- value | Median (range) | p- value | Median (range) | p- value | Median (range) | p- value | Median (range) | p- value | Median (range) | p- value | |
Histological type
| NS | NS | NS | NS | NS | NS | |||||||
Clear cell | 99 | 20 (0-300) | 0 (0-100) | 80 (0-285) | 60 (0-300) | 4.5 (0-257) | 127.5 (0-300) | ||||||
Papillary | 9 | 30 (0-270) | 0 (0-25) | 140 (0-270) | 75 (0-285) | 24 (0-202) | 120 (0-200) | ||||||
Chromophobe | 5 | 135 (10-180) | 1.5 (0-45) | 15 (0-160) | 22.5 (0-190) | 1 (0-52) | 100 (20-180) | ||||||
Other | 5 | 60 (0-300) | 1 (0-20) | 20 (2-80) | 22.5 (0-130) | 0 (0-244) | 120 (30-120) | ||||||
Histological grade
| NS | 0.0552 | 0.0126 | NS | 0.0325 | NS | |||||||
I/II | 52 | 52.5(0-300) | 0 (0-45) | 65 (0-237.5) | 38.75 (0-285) | 46 (0-257) | 127.5 (0-300) | ||||||
III/IV | 66 | 15 (0-300) | 0.35 (0-100) | 90 (0-285) | 67.5 (0-300) | 1 (0-205) | 120 (0-300) | ||||||
Stage
| NS | 0.0141 | 0.0703 | NS | NS | NS | |||||||
Ι/II | 43 | 30 (0-300) | 0(0-45) | 45(0-270) | 37.5 (0-285) | 33 (0-244) | 97.5 (1.5-300) | ||||||
ΙΙI/IV | 63 | 20 (0-300) | 0.75(0-100) | 80 (0-285) | 60 (0-300) | 1 (0-257) | 120 (0-300) | ||||||
Presence of metastasis
| NS | 0.0099 | 0.0001 | 0.0155 | 0.0426 | 0.0371 | |||||||
Absence | 30 | 30 (0-300) | 0 (0-45) | 20 (0-270) | 20 (0-160) | 44.5 (0-244) | 90 (0-250) | ||||||
Presence | 64 | 17.5 (0-300) | 0.5 (0-100) | 95 (0-285) | 75 (0-300) | 1 (0-257) | 135 (5-300) | ||||||
Disease progression
| NS | NS | NS | 0.0401 | NS | NS | |||||||
Absence | 19 | 20 (0-200) | 0.75 (0-10) | 120 (16-270) | 50 (0-180) | 1 (0-257) | 140 (10-300) | ||||||
Presence | 42 | 12.5 (0-300) | 0.75 (0-100) | 90 (0-285) | 95 (205-300) | 10(0-207) | 145 (5-300) | ||||||
Total number of metastases
| 94 | R = 0.3458, p = 0.0006 | R = 0.3333, p = 0.0010 | NS | R = 0.2945, p = 0.0040 | R = -0.2212, p = 0.0331 | NS | ||||||
Patients’ age
| 118 | R = 0.2228, p = 0.0871 | NS | NS | NS | NS | NS |
Immunohistochemical assessment of SOCS-3 and p-STAT-3 expression in RCC and correlation with clinicopathological parameters
Relationship of IL-6, IL-8, SOCS-3, CXCR2 and p-STAT-3 expression with VEGF
Relationship of VEGF, IL-6, IL-8, SOCS-3, CXCR2 and p-STAT3 expression with microvascular characteristics
MVD | TVA | Major axis length | Minor axis length | Area | Perimeter | Feret diameter | Compactness | Shape factor | |
---|---|---|---|---|---|---|---|---|---|
IL-6 | NS | NS | NS | NS | NS | NS | NS | NS | NS |
IL-8 | R = -0.1873, p = 0.0432** | NS | NS | NS | NS | NS | NS | NS | NS |
CXCR2 | NS | NS | R = -0.1884, p = 0.0419 | R = -0.1804, p = 0.0516 | R = -0.1541, p = 0.0972 | R = -0.1818, p = 0.0497 | R = -0.1541, p = 0.0972 | R = -0.1756, p = 0.0582 | R = 0.1758, p = 0.0579 |
SOCS-3 | NS | NS | NS | NS | NS | NS | NS | R = -0.1686, p = 0.0693 | R = 0.1684, p = 0.0695* |
pSTAT3 | NS | NS | NS | NS | NS | NS | NS | NS | NS |
VEGF | NS | R = 0.2166, p = 0.0230 | NS | NS | R = 0.1967, p = 0.0394 | NS | R = 0.1967, p = 0.0394 | NS | NS |
Relationship of VEGF and microvascular characteristics with clinicopathological features
Relationship of IL-6, IL-8, SOCS-3, CXCR2 with p65/RelA, HIF-1a, p53, p-JAK2 kinase and p-c-Jun
Survival analysis
Variables | Log-rank test (p-value) |
---|---|
Age
| |
<61 vs ≥61 years
| 0.1142 |
Gender
| |
Male vs Female
| 0.5701 |
Histological type
| |
Clear cell vs non- clear cell
| 0.2441 |
Histological grade
| |
I/ II vs III/IV
| 0.2378 |
Stage
| |
I/II vs III/IV
|
0.0002
|
Total number of metastases
| |
1 vs more
| 0.2787 |
IL-6 H-score
| |
<24 vs ≥24
| 0.8718 |
IL-8 H-score
| |
Negative vs positive
| 0.1311 |
CXCR2 H-score
| |
<80 vs ≥80
|
0.0293
|
SOCS3 H-score
| |
<60 vs ≥60
|
0.0478
|
p-STAT3 H-score
| |
<4 vs ≥4
|
0.0730
|
VEGF H-score
| |
<120 vs ≥120
| 0.8804 |
MVD
| |
<125 vs ≥125
| 0.9391 |
TVA
| |
<30069.62 vs ≥30069.62 | 0.2134 |
Area
| |
<222.345 vs ≥222.345
| 0.1057 |
Major axis length
| |
<24.771 vs ≥24.771
| 0.4925 |
Minor axis length
| |
<9.541 vs ≥9.541
| 0.3642 |
Perimeter
| |
<74.329 vs ≥74.329
| 0.1194 |
Shape factor
| |
< 0.495 vs ≥0.495
| 0.3118 |
Feret diameter
| |
<16.826 vs ≥16.826
| 0.1057 |
Compactness
| |
<25.361 vs ≥25.361
| 0.2241 |
HR | P value | 95% confidence interval of HR | ||
---|---|---|---|---|
SOCS3 H-score | 1,004 | 0,045 | 1,000 | 1,008 |
Tumour stage | 1,734 | <0.001 | 1,277 | 2,355 |